A Simple Key For Nemifitide diTFA Unveiled
MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review to evaluate a number of intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Major demo goals were being to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymy